MomsSpaghetti
5 minutes ago
MM-120, MindMed’s lead drug candidate, represents a potentially transformative treatment for patients with generalized anxiety disorder (GAD) and other mental health conditions. The promising progress in its development, particularly its Phase 3 trials, suggests a bright future for the drug, MindMed